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Abstract: Menopause is an inevitable developmental event that women encounter at an age of
42–54 years. The drop of estrogen levels that accompanies cessation of menstruation is associated
with multiple vasomotor, physical, neuropsychological, and sexual symptoms, which may hamper
quality of life. This study aimed to examine the severity of psychological symptoms and their
correlates among peri- and postmenopausal Emirati women (N = 60, mean age = 54.88 ± 6 years).
Participants were interviewed using the Menopause-Specific Quality of Life (MENQOL) and attitudes
toward menopause scale (ATMS). In four path analysis models, vasomotor symptoms, weight gain,
and fatigue had significant direct effects on symptoms of anxiety, depression (only weight gain
and fatigue), and psychological distress. Fatigue significantly mediated the effects of vasomotor
symptoms and weight gain on symptoms of anxiety, depression (only vasomotor symptoms),
psychological distress, and memory problems. These models explained 47.6%, 44.5%, 56.6%, and 29.1%
of the variances in anxiety, depression, psychological distress, and memory problems, respectively.
Participants with more severe menopausal symptoms expressed more negative attitudes toward
menopause though regression analysis revealed that only vasomotor symptoms could significantly
contribute to ATMS scores. In conclusion, psychological distress is widespread among menopausal
women, and it is associated with vasomotor symptoms, fatigue, and change of body composition
(obesity). Psychological symptoms, along with vasomotor symptoms, express a key link to negative
attitudes toward menopause. Therefore, interventional strategies that target psychological distress
may promote coping with midlife transition and improve mental health among menopausal women.
Keywords: fatigue; depression; anxiety; sleep; memory; psychological distress; vasomotor symptoms;
sexual symptoms; body weight/obesity; menopause; quality of life; attitudes toward menopause;
Arab; Emirate

1. Introduction
Menopause transition is characterized by a massive drop of estrogen levels (the main feminine
sex hormone), ovarian failure, and menstrual irregularities [1]. Menopause is described as cessation of
menses for 12 sequential months after the last period [2]. It is a universal physiological condition that
annually affects more than 500 million women aged 42 to 55 years with an average age of onset of
51 years [2–4]. Hormonal changes that accompany the onset of menopause trigger the development of
several physical, sexual, vasomotor, and psychological symptoms [4].
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Compared with premenopausal women, menopausal women express a wide range of psychological
symptoms including poor memory and concentration, depression, anxiety, insomnia, fatigue, irritability,
and a high level of distress, which may impede coping and decrease quality of life in this group [5].
Furthermore, severe neuropsychiatric symptoms may reflect the development of age-related pathologies
such as cognitive impairment associated with Alzheimer’s disease, especially during the prodromal
stage, but get misinterpreted as symptoms of natural aging and go uncared for [6], which can have
serious health-related drawbacks.
The Arab world extends on an area of 5 million square miles in 2 major continents, Asia and Africa.
It comprises 22 countries inhabited by 423 million people who share the same language, as well as the
same cultural, historical, and religious heritage [7,8]. Although several studies assessed menopausal
symptoms in women from different Arab countries, vasomotor and physical symptoms have been
the focus of most studies [4,9,10] while less attention has been paid to neuropsychiatric symptoms.
In this light, the current study attempts to fill this gap by exploring the nature of common menopausal
psychological symptoms among Emirati menopausal women as a sample of Arab women.
Forgetfulness and reductions in attention, processing speed, and verbal fluency (indicated by
difficulty finding words) are common cognitive problems endorsed by menopausal women and
women in the menopause transition [11,12]. Declines in memory represent the second most frequent
menopausal symptom after vasomotor symptoms and joint stiffness, and the severity of these symptoms
can be quite alarming [1,12]. Estrogen deficiency alters brain structure and function, resulting in
symptoms of cognitive aging and susceptibility to Alzheimer’s disease in genetically vulnerable
individuals [11]. In particular, estrogen, a neurosteroid with multiple neuroprotective effects, interacts
with brain cells through its widely distributed estrogen receptors (ERs) β and α to regulate key
processes relevant to executive functioning and memory: signal transduction and neurotransmission
(e.g., of acetylcholine, serotonin, noradrenaline, and glutamate) in the prefrontal cortex, synaptic
plasticity, production of neurotrophic factors such as nerve growth factor, neurite growth, dentate
gyrus neurogenesis, DNA repair, mitochondrial production of adenosine triphosphate, and production
of internal antioxidants [11,13–15].
Symptoms of depression, anxiety, and sleep disturbance are other neuropsychiatric symptoms
linked to cognitive performance at midlife transition in women, but they do not explain memory
declines in menopause [12]. Women are at a greater risk for depression than men, and such risk
heightens with aging [16]. Women in menopausal transition are at two- to fourfold higher risk
for major depressive disorders than premenopausal women [17]. Perimenopausal women often
experience different depressive symptoms (e.g., low mood, lack of motivation, lack of pleasure
sense, and disrupted sleep), which can severely impair their quality of life [17]. A recent large-scale
cross-sectional study reported a diagnosis of depression (on the Center for Epidemiologic Studies
Short Depression Scale-10) among 18.4% of community-dwelling middle-aged women in Canada.
Women experiencing menopause before the age of 40 endorsed the highest incidence of depression
(odds ratio = 1.45; CI: 1.07–1.97) [18]. Likewise, surveying Turkish menopausal women with Beck
depression inventory (BDI) revealed that 27.5% of them are affected by depression [19].
Menopause-related estrogen decline may trigger mood dysregulation by impeding the
production of major neuroprotective factors (e.g., brain-derived neurotrophic factor) and, by altering
neurotransmission, it interferes with the synthesis of catecholamines such as noradrenaline and
upregulates 5-hydroxytryptamine (serotonin) (5-HT2A) receptor [1,11]. The latter contributes to hot
flashes by modulating the set point temperature [1]. Vasomotor symptoms (e.g., hot flashes and
night sweats), the cardinal symptoms of menopause, are experienced by 85% of perimenopausal
women [1,12]. These symptoms are quite bothersome, and they represent a major risk factor for sleep
disturbances as well as for anxiety and/or depressive symptoms [16,18]. A current study comprising
a sample of 13,216 Canadian women aged 45 to 64 years reports increased severity of vasomotor
symptoms and higher odds of depression (odds ratio = 1.21; CI: 1.02–1.44) among postmenopausal
women on hormonal replacement therapy (HRT, also known as menopause hormone treatment) [18].
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Mood changes that affect menopausal women are associated with numerous factors other than
hormonal declines such as genitourinary symptoms (e.g., vaginal dryness/dyspareunia), less education,
nonwhite ethnicities, history of smoking, history of anxiety and postpartum depression, nulliparity,
obesity, stressful life events, poor social support and partner death, low self-esteem, unemployment,
encountering multiple stressors, and poor coping style [11,16,18,20].
Advanced age is associated with disturbed sleep (insomnia, nighttime awakening, or waking
early) both in men and women. However, sleep loss in women is approximately twice that of
men [1,12]. Both subjective self-reports and actigraphy studies uncover poor quality and quantity
of night sleep among women during their late reproductive years, especially before the time of
menses. Sleep problems that occur because of night sweat and hot flashes are tightly linked to
hormonal declines [1]. Meanwhile, sleep problems in women aged 40 years and older are attributed
to many factors other than estrogen deficiency such as having anxiety and/or depressive disorders,
socio-economic difficulties, white race, and marital conflicts [1,11,21]. Daytime fatigue and sleepiness
associated with inadequate sleep may contribute to injury, depressive symptoms, and poor quality of
life [1].
Menopausal symptoms such as lack of energy and fatigue, experienced by 43.9–64.7% of
menopausal women, are strongly associated with exhaustion and burnout, which may seriously
compromise quality of life of affected women [22–24]. Fatigue is described as a feeling of lack of energy,
weariness, loss of drive, decrease or loss of ability to sustain even routine activities, overwhelming
feeling of tiredness, exhaustion, and physical or mental strain that occurs even without conspicuous
effort. Pathological fatigue is an intensified level of the common “physiological” fatigue, and it may be
evoked by pervasive pathologies [24–26]. The relation between fatigue and stress is dynamic, and it
drastically changes during menopausal transition [22]. In fact, chronic fatigue in humans is described as
a stress-related condition that involves numerous systemic dysfunctions, which alter homeostasis and
hinder women’s ability to bounce back from either fatigue or distress [5,22]. For instance, dysregulation
of the hypothalamic–pituitary–adrenal axis and persistent activation of the sympathetic nervous system
are common in people with chronic fatigue syndrome, and they trigger a wide range of symptoms
that can induce excessive suffering [5,26]. Studies on menopause-specific fatigue, fatigue explained
mainly by endorsing menopause transition rather than suffering insomnia or depression, are relatively
scarce [23]. However, evidence denotes strong connections between menopausal fatigue and emotional
negativity (depressed mood and perceived stress) during menopause [27]. Fatigue in general is usually
accompanied by several unpleasant symptoms such as pain, distress, insomnia, impatience, irritability,
and mood disturbances [5,21,23,26,28]. In this regard, menopause-related fatigue is reported to be a
key source of exhaustion, burnout, and low resilience among working nurses. Meanwhile, resources of
social and organizational support could not mitigate its effects. Hence, working menopausal women
may require specific interventions that promote processes of energy recovery [22]. Research shows
that menopause-specific fatigue can be alleviated by pharmacologic treatments (e.g., armodafinil,
a wakefulness-promoting agent and a central nervous system stimulant) and non-pharmacologic
interventions such as hypnosis [23,29].
Weight status is a key effector of menopausal and mood symptoms in peri- and postmenopausal
women [27,30]. Aging is associated with oxidative stress and chronic inflammation, which promote
the buildup of saturated ceramide and diacylglycerol fatty acids resulting in increased total body fat
and visceral adipose tissue [31,32]. Emotional distress associated with menopausal symptoms boosts
the production of cytokines and free radicals resulting in more fat deposition/obesity [27]. On the other
side, obesity contributes to the development of neurodegenerative disease such as depression, anxiety,
and Alzheimer’s disease through a complex mechanism. On one hand, cerebral insulin resistance
develops in obese individuals due to depletion of adiponectin—an adipose tissue-derived adipokine
that regulates neurogenesis and the metabolism of lipids and glucose [33]. On the other hand, obesity
involves pathological reshaping of gut microbiome structure and activation of major oxidative and
inflammatory pathways, which fuel neuronal inflammation—an essential aspect in the development
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of mood and cognitive disorders [34,35]. Moreover, research shows that high fat mass interferes
with the effect of therapeutic interventions used to manage menopausal symptoms such as physical
exercise [27].
Attitudes toward menopause represent believes held by women about bodily and role changes
that are associated with feminine aging. Some psychologists view psychological complaints expressed
by menopausal women as reflections of cultural expectations [36]. In addition, research highlights
associations between negative attitudes toward menopause and the severity of menopausal symptoms
(e.g., vasomotor symptoms and fatigue) [10] and psychological symptoms [19]; however, findings are
inconsistent. Attitudes toward menopause vary considerably between different cultures. They tend to
be more positive when associated with positive changes in social status [19]. For example, menopausal
women in Japan express more positive attitudes toward menopause compared with women in Western
countries [36]. In this light, attitudes might threaten femininity in societies that consider it as a partial
death of a woman [36]. Several factors affect the extent to which menopausal women develop positive
or negative attitudes toward this life transition. An available systematic review reports that husbands’
perceptions of and attitudes toward menopause may largely influence marriage relationships, women’s
menopausal symptoms, and attitudes toward menopause [37]. The term used to express menopause
in Arabic is “sen al yaas”, which means “the age of despair or hopelessness”. Despite the negative
connation associated with menopause in Arab countries, in depth investigations show that Arab
postmenopausal women receive proper support from their husbands, participate in religious activities
that they could not take part in before, and demonstrate more socially-active roles than before [2,38].
In addition, the term “age of despair or hopelessness” has been recently changed in the media by a
more positive term “the age of wisdom or respect”.
A former systematic review reports a great variability in the age of onset of menopause and the
occurrence of vasomotor symptoms worldwide, with the lowest age occurring in Asia (42.1–49.5 years)
compared with Europe and North America (50.1–52.8 years and 50.5–51.4 years, respectively) [39].
The United Arab Emirates (UAE) is a small country located in the Gulf region in Asia. It has witnessed
remarkable improvements in the health system during the last few decades, which were associated
with increased life expectancy (up to 83.4 years) [2,40]. The median age of menopause in the UAE
is 48 years (mean age = 47.3 ± 3.29, range 40–59), which is significantly lower than the median age
reported in Western countries (50.3 years) [40]. Given the remarkable increase of lifespan in the
UAE, women are expected to endure postmenopausal symptoms and complications for around one
third of their lives [2]. Although menopausal symptoms have been previously evaluated in the UAE,
less attention has been paid to neuropsychiatric symptoms such as depression, anxiety, memory,
and sleep problems [4]. Similarly, attitudes toward menopause have been studied in the UAE before [2].
However, the association between menopausal symptoms and attitudes toward menopause in the UAE
has not been assessed yet. Therefore, the current study offers in depth exploration of psychological
climacteric symptoms and addresses the relationship between menopausal symptoms and attitudes
toward menopause.
Based on the aforementioned background, this study aimed to examine the direct and indirect
effects of vasomotor symptoms and weight gain on psychological symptoms of menopause. Specifically,
we hypothesized that vasomotor symptoms and weight gain contribute to sleep loss/difficulty sleeping
and fatigue, which in turn contribute to anxiety and depressive symptoms, psychological distress,
and memory problems (Figure 1). We also examined the association between neuropsychiatric
climacteric symptoms and other factors documented in the literature to contribute to distress, e.g.,
sexual symptoms, age, menopausal status (perimenopausal vs. postmenopausal), short time since
menopause onset, level of education, smoking, employment, marital status, and HRT use [30,40].
The second aim of the current study was to identify correlates of attitudes toward menopause.
In particular, we postulated that women experiencing more severe symptoms would endorse more
negative attitudes toward menopause.
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Figure 1. Hypothesized model of the relationships between vasomotor symptoms, weight gain,
Figure 1. Hypothesized model of the relationships between vasomotor symptoms, weight gain,
difficulty sleeping, fatigue, and psychological variables.
difficulty sleeping, fatigue, and psychological variables.
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Hypothesis
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Hypothesis
(H4a,b,c,d). Difficulty sleeping contributes to anxiety, depression, psychological distress,
2. Materials4a,b,c,d
and Methods
and memory problems.
2.1. Study Design, Participants, and Procedure
Hypothesis 5a,b,c,d (H5a,b,c,d). Fatigue contributes to anxiety, depression, psychological distress,
This study
is a secondary analysis based on data of a formerly published study [4]. In brief, a
and memory
problems.
multistage random sample comprising 70 women aged 40–64 years was collected from two public
health care centers in Dubai between April and August 2018. Data were collected through face-to2. Materials and Methods
face interviews that were conducted by five trained nurses. The original sample included 10
premenopausal
which
not included in the current analysis because the literature
2.1.
Study Design, women,
Participants,
andwere
Procedure
reports significant differences in neuropsychiatric symptoms between premenopausal women and
is a secondary analysis
based
on data of a formerly published study [4]. In brief,
theirThis
peri-study
and postmenopausal
counterparts
[5,17].
a multistage random sample comprising 70 women aged 40–64 years was collected from two public
health
care Instruments
centers in Dubai between April and August 2018. Data were collected through face-to-face
2.2. Study
interviews that were conducted by five trained nurses. The original sample included 10 premenopausal
Participants of this study were interviewed face-to-face using a structured questionnaire that
women, which were not included in the current analysis because the literature reports significant
consisted of three sections. The first section involved assessment of sociodemographic, clinical, and
differences in neuropsychiatric symptoms between premenopausal women and their peri- and
menopause-related data, e.g., age, education, smoking, health status, date of the last menses, HRT
postmenopausal counterparts [5,17].
use, etc. The second section comprised the Menopause-Specific Quality of Life (MENQOL) scale
developed by Hilditch et al. [41]. The MENQOL scale contains 29 items, which explore the experience
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2.2. Study Instruments
Participants of this study were interviewed face-to-face using a structured questionnaire that
consisted of three sections. The first section involved assessment of sociodemographic, clinical,
and menopause-related data, e.g., age, education, smoking, health status, date of the last menses,
HRT use, etc. The second section comprised the Menopause-Specific Quality of Life (MENQOL)
scale developed by Hilditch et al. [41]. The MENQOL scale contains 29 items, which explore the
experience of different menopausal symptoms as endorsed or not endorsed as well as the degree of
being bothered by symptoms on a scale that ranges from 0 (not at all bothered) to 6 (extremely bothered).
Symptoms assessed by the MENQOL are distinguished into four domains: vasomotor (items 1–3),
psychosocial (items 4–10), physical (items 11–26), and sexual (items 27–29) [9,42]. The questionnaire
was translated into Arabic by a professional translator. The Arabic version was checked by a bilingual
expert who back translated it into English. Then, a panel comprising a professor and a consultant
specialized in obstetrics and gynecology checked the content validity of the scale, which was then
tested for reliability in a small-scale sample (15 women) by Smail and others [4]. Reliability of the
MENQOL, as evaluated in our sample, is excellent (α = 0.96). The third section comprised the attitudes
toward menopause scale (ATMS) developed by Neugarten et al. (reviewed in [2]). ATMS is a four-point
Likert scale (1 strongly agree, 2 agree, 3 disagree, 4 strongly disagree), which consists of 34 items,
which examine attitudes toward menopause in general. For each item, responses range from strongly
agree to strongly disagree. Positive items are reverse coded. Accordingly, greater ATMS scores reflect
positive attitudes and low scores reflect more negative attitudes toward menopause. Validity and
reliability of ATMS are documented in the literature [2]. Reliability of ATMS, as evaluated in our
sample, is acceptable (α = 0.79).
2.3. Ethical Considerations
The original study was approved by the Research and Ethics Committee at Zayed University and
Dubai Health Authority Research Office. Permissions from the selected primary health care centers
were obtained. Selected women were informed that data are collected for scientific purposes only,
and they were invited to participate in the study on a voluntary basis. A consent form was given to
each participant, and they were assured about the confidentiality, anonymity, and security of data.
To protect the confidentiality of the participants, data collected were stored in a locked file cabinet in a
supervised office during the study. After the end of data collection, all identifying personal information
were destroyed.
2.4. Statistical Analysis
For analysis, we converted item scores of the MENQOL scale, which represent subject responses,
into a score ranging from 1 (not experiencing a symptom) to 8 (extremely bothered by the symptom).
The literature indicates that item scores of the psychosocial domain of the MENQOL correlate with
measures of depression and psychological health such as BDI and the Short Form-36 questionnaire.
In addition, BDI scores correlate with overall scores of the MENQOL scale [42]. Therefore, we examined
the scale for other items related to psychological health. We found that the physical domain contains
several items that express psychological problems: items 13 “feeling tired and worn out”, 14 “difficulty
sleeping”, 17 “decrease in stamina”, and 18 “feeling lack of energy”. Similar items are included in the
Depression Anxiety Stress Scale—a measure of depression, anxiety, and psychological stress [43–45].
Besides, insomnia and fatigue “e.g., feeling tired or lacking energy” are reported to be psychological
symptoms commonly experienced by menopausal women [5,22,27]. Accordingly, we conducted
exploratory factor analysis with Oblimen rotation, and it revealed that some items of the physical
domain cross-loaded on other domains (Supplementary Materials). Hence, we reconstructed the
psychosocial domain in the current analysis to comprise 2 extra items by adding item 14 and item 17.
Internal consistency reliability of our psychosocial domain of the MENQOL is excellent (α = 0.90).
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3. Results
Participant women (mean age = 54.88 ± 6 years) were mostly married (71.2%), while 10.2%
were single or widowed and 8.5% were divorced. Only 1.7% graduated the university, 8.3% were
illiterate, and the rest of the participants (16.7%, 21.7%, and 26.7%) had elementary school, junior high
school, and high school education, respectively. Most women were unemployed (83.4%). Only 6.7%
were smokers. Around half the participants never used (45%) or used (55%) oral contraceptive
pills. The majority of women were postmenopausal (86.7%), while only 13.3% were perimenopausal.
The average time elapsed since the last menstrual period was 6.13 ± 5.22 years. Only 10% reported
lifetime use of HRT, and 5% were current HRT users. Most participants (61.7%) rated their health
condition as good, while 20% rated it as very good, and 18.3% rated it as poor.
Table 1 shows the percentage of participants encountering psychological symptoms and the extent
to which they are bothered by these symptoms. Fatigue expressed as “feeling tired or worn out”
and “feeling a lack of energy” was the most experienced (65.0%) and the most bothersome symptom
(median = 4, IQR = 5). Difficulty sleeping was the second most frequent (61.7%) and the second
most bothersome symptom (median = 4, IQR = 5) followed by “feeling anxious or nervous” (58.3%),
“experiencing poor memory” (55.0%), and “feeling depressed, down or blue” (50.0%).
Table 1. Prevalence of psychological symptoms among the study participants.

Symptoms

With Experience
NO (%)

Without
Experience
NO (%)

Degree of Being
Bothered by Symptoms
Median (IQR)

Being dissatisfied with my personal life
Feeling anxious or nervous
Experiencing poor memory
Accomplishing less than I used to
Feeling depressed, down or blue
Being impatient with other people
Feelings of wanting to be alone
Feeling tired or worn out
Difficulty sleeping
Decrease in stamina
Feeling a lack of energy
FatigueN
AnxietyN
DepressionN
Psychological distressN

16 (26.7%)
35 (58.3%)
33 (55.0%)
25 (41.7%)
30 (50.0%)
28 (46.7%)
21 (35.0%)
39 (65.0%)
37 (61.7%)
29 (48.3%)
39 (65.0%)
Minimum = 2
Minimum = 2
Minimum = 4
Minimum= 9

44 (73.3%)
25 (41.7%)
27 (45.0%)
35 (58.3%)
30 (50.0%)
32 (53.3%)
39 (65.0%)
21 (35.0%)
23 (38.3%)
31 (51.7%)
21 (35.0%)
Minimum = 16
Minimum = 16
Minimum = 11
Maximum= 69

1 (2)
3 (5)
3 (4)
1 (3)
2 (4)
1 (4)
1 (3)
4 (5)
4 (5)
1 (4)
4 (5)
7.5 (9)
5.5 (8)
7 (11)
21.5 (23)

N: Variables are computed according to Figure 2.

Weight gain was experienced by 63.3% of the participants, and the degree of being bothered by
this symptom in the whole sample was moderate (3.87 ± 2.48). This variable was involved in path
analysis and regression models as a predictor.
Most psychological variables addressed in this study (variables 1 to 6 in Table 2) demonstrated
significant positive correlations with vasomotor symptoms, sexual symptoms, weight gain, and total
MENQOL scores. We found no associations between scores of all psychological variables with any
sociodemographic and clinical characteristics of the participants such as age, level of education,
marital status, menopausal status, smoking, use of HRT, occupation, health status, and age of onset of
menopause (Supplementary Materials).

Int. J. Environ. Res. Public Health 2020, 17, 5028

9 of 19

Table 2. Correlations between psychological variables and attitudes toward menopause with different menopausal symptoms.
Variables
1. Anxiety
2. Depression
3. Psychological distress
4. Memory problems
5. Difficulty sleeping
6. Fatigue
7. Vasomotor symptoms
8. Sexual symptoms
9. Total MENQOL
10. ATMS
11. Weight gainN

1

2

3

4

5

6

7

8

9

10

–
0.793 **
0.893 **
0.537 **
0.214
0.593 **
0.540 **
0.426 **
0.823 **
−0.374 **
0.427 **

–
0.861 **
0.517 **
0.242
0.491 **
0.486 **
0.427 **
0.738 **
−0.309 *
0.437 **

–
0.654 **
0.457 **
0.664 **
0.607 **
0.443 **
0.898 **
−0.390 **
0.476 **

–
0.177
0.510 **
0.370 **
0.087
0.582 **
−0.268 *
0.372 **

–
0.361 **
0.449 **
0.260 *
0.411 **
−0.191
0.121

–
0.540 **
0.475 **
0.826 **
−0.304 *
0.372 **

–
0.435 **
0.681 **
−0.358 **
0.225

–
0.628 **
−0.201
0.368 **

–
−0.334 **
0.499 **

–
−0.350 **

* p < 0.05, ** p < 0.01, MENQOL: Menopause-Specific Quality of Life scale, ATMS: attitudes toward menopause scale, N: Weight gain is expressed as the degree of being bothered by
increased body weight; it ranged from 1 (no weight gain) to 8 (being extremely bothered by weight gain).

Int. J. Environ. Res. Public Health 2020, 17, 5028

10 of 19

To test hypotheses 1 to 5, four path models were conducted to examine (a) direct associations of
vasomotor symptoms, weight gain, difficulty sleeping, fatigue, with symptoms of anxiety, depression,
psychological distress, and memory problems; and (b) indirect associations of vasomotor symptoms
and weight gain with anxiety, depression, psychological distress, and memory problems through
difficulty sleeping and fatigue. Path models comprising difficulty sleeping were not significant,
and thus were trimmed to improve model fit. Table 3 shows that the four trimmed path analysis
models, with effects of vasomotor symptoms and weight gain mediated by fatigue, had acceptable fit
on all measures, albeit RMSEA was a bit high in models predicting anxiety and psychological distress
(0.090 and 0.096, respectively). The full path models accounted for 47.6%, 44.5%, 56.6%, and 29.1% of
the variances in anxiety, depression, psychological distress, and memory problems, respectively.
Table 3. Summary of model-data fit and the percentages of variance explained by trimmed path models.
Outcome Variables

χ2

P

CFI

TLI

RMSEA

R2

SE

P

95% CI

Anxiety
Depression
Psychological distress
Memory problems

5.932
4.203
6.180
4.731

0.204
0.379
0.186
0.316

0.976
0.997
0.977
0.988

0.941
0.993
0.942
0.970

0.090
0.029
0.096
0.056

0.476
0.445
0.566
0.291

0.088
0.090
0.080
0.102

0.009
0.013
0.008
0.013

0.298 to 0.591
0.258 to 0.557
0.406 to 0.671
0.115 to 0.425

N.B. Given that sexual symptoms had strong positive correlations with symptoms of anxiety, depression,
and psychological distress (Table 2), they were included in initial models as a predictor of these symptoms.
However, these models exhibited poor fit, even after trimming insignificant paths. Associations involving sexual
symptoms were less significant (all p values < 0.05) compared with those involving vasomotor symptoms and
weight gain (p values ranged from <0.05 to <001). Therefore, sexual symptoms were removed from all models,
which resulted in good model-data fit.

In all models, as shown in Figure 3, there was a statistically significant path coefficient for the
direct effect of vasomotor symptoms on fatigue (β = 0.51, p = 0.001) while the effect of weight gain on
fatigue approached statistical significance (β = 0.28, p = 0.05)—the full model accounted for 34.4% of
the variance in fatigue (p = 0.009, 95% CI: 0.167 to 0.478). Only vasomotor symptoms were significantly
associated with difficulty sleeping (β = 0.47, p= 0.001), and the full model accounted for 21.9% of the
variance in difficulty sleeping (p = 0.001, 95% CI: 0.115 to 0.425).
According to Figure 3a, there were statistically significant path coefficients (p < 0.05) for the
direct effects of vasomotor symptoms, weight gain, and fatigue on anxiety symptoms (β = 0.21, 0.30,
and 0.41, respectively). Both vasomotor symptoms and weight gain had significant indirect effects
on anxiety through fatigue (β = 0.15 and 0.19, p = 0.008 and 0.042, respectively). Figure 3b shows a
direct positive effect of weight gain on depression (β = 0.32, p = 0.006) along with a significant indirect
effect of vasomotor symptoms through fatigue (β = 0.22, p = 0.011) while the indirect effect of weight
gain through fatigue tended to be significant (β = 0.28, p = 0.050). According to Figure 3c, vasomotor
symptoms, weight gain, and fatigue had positive direct effects on psychological distress (β = 0.32, 0.30,
and 0.39; p = 0.018, 0.002, and 0.005, respectively). Fatigue significantly mediated the relationship
of vasomotor symptoms and weight gain with psychological distress (β = 0.54 and 0.70, p = 0.002,
and 0.045). Only fatigue expressed a significant direct effect on memory problems (β = 0.37, p = 0.042)
(Figure 3d). It also significantly mediated the effect of vasomotor symptoms and weight gain (β = 0.07
and 0.09, p < 0.05). Please check Supplementary Materials for further details.
Women taking part in this study had an average attitude score of 2.45 ± 0.27 (min = 1.71,
max = 3.12). According to Table 4, more than two thirds of the participants (71.7%) agreed or strongly
agreed that “women should expect some trouble during menopause” while 76.7% viewed “menopause
as one of the biggest changes that happen in a woman’s life” and agreed that “a woman should see
a doctor at menopause”; these two attitudes were the most negative ones averaging 1.98 and 1.95,
respectively. More than half of the participants (61.7%) agreed or strongly agreed that menopausal
women feel freer to do things for themselves. Most participants (around 75%) disagreed that most
women become disagreeable during menopause, menopausal women do not consider themselves
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real women, and that they consider menopause as an excuse for getting attention. The least endorsed
attitude (15%) was that menopausal women are more interested in sex than they were before.
Table 4. The percentage of participants who agreed and strongly agreed to items of the attitudes toward
menopause scale, along with mean ± SD for each item.
Agreement (%)

Mean ± SD

1

A woman should see a doctor at menopause

46 (76.7%)

1.95 ± 0.84

2

Menopause is one of the biggest changes that happens in a woman’s life

46 (76.7%)

1.98 ± 0.82

3

A woman is concerned about how her husband will feel about her
after menopause

35 (58.3%)

2.14 ± 0.85

4

Menopause is an unpleasant experience

37 (61.7%)

2.19 ± 0.82

5

After the change of life, a woman feels freer to do things for herself

37 (61.7%)

2.80 ± 0.71

6

Women generally feel better after menopause

29 (48.3%)

2.52 ± 0.71

7

Women are generally calmer and happier after the change of life

28 (46.7%)

2.50 ± 0.71

8

A woman has a broader outlook on life after the change

28 (46.7%)

2.61 ± 0.74

9

Menopause is a disturbing thing that women naturally dread

36 (60%)

2.21 ± 0.81

10

Women should expect some trouble during menopause

43 (71.7%)

2.19 ± 0.71

11

A woman’s body may change in menopause, but otherwise, she doesn’t
change much

35 (58.3%)

2.61 ± 0.83

12

It is no wonder women feel down in the dumps at the time of menopause

31 (51.7%)

2.39 ± 0.79

13

Life is more interesting for a woman after menopause

24 (40%)

2.47 ± 0.80

14

Changes inside the body that women cannot control cause all the trouble during
menopause

33 (55%)

2.37 ± 0.72

15

A woman gains more confidence in herself after the change of life

23 (38.3%)

2.39 ± 0.77

16

Going through menopause really does not change a woman in any
important way

21 (35%)

2.29 ± 0.77

17

Women worry about losing their minds during menopause

23 (38.3%)

2.54 ± 0.85

18

Women think of menopause as the beginning of the end

24 (40%)

2.55 ± 0.86

19

The only difference between a woman who has been through menopause and
one who has not is that one menstruates and the other doesn’t

30 (50%)

2.54± 0.89

20

In truth, just about every woman is depressed about menopause

40 (66.7%)

2.24± 0.75

21

Women often use the change of life as an excuse for getting attention

14 (23.3%)

2.74 ± 0.66

22

After the change of life, women do not consider themselves real women

14 (23.3%)

2.75 ± 0.76

23

It’s not surprising that most women become disagreeable during menopause

15 (25%)

2.78 ± 0.77

24

After the change of life, a woman has a better relationship with her husband

23 (38.3%)

2.34 ± 0.79

25

Many women think menopause is the best thing that ever happened to them

26 (43.3%)

2.50 ± 0.84

26

After the change of life, a woman becomes more interested in community affairs
than before

40 (66.7%)

2.71 ± 0.70

27

Women who have trouble with menopause are usually those who have nothing
to do with their time

33 (55%)

2.60 ± 0.72

28

Women who have trouble with menopause are those who are expecting it

26 (43.3%)

2.36 ± 0.74

29

Women often become self-centered at the time of menopause

34 (56.7%)

2.34 ± 0.78

30

A woman in menopause is apt to do crazy things she herself does not understand

18 (30%)

2.79 ± 0.73

31

Menopause is a mysterious thing that most women don’t understand

32

After menopause, a woman is more interested in sex than she was before

33
34

Items

25 (41.7%)

2.54 ± 0.86

9 (15%)

2.02 ± 0.60

Unmarried women have a harder time than married women do at the time
of menopause

22 (36.7%)

2.50 ± 0.84

A good thing about menopause is that a woman can quit worrying about
becoming pregnant

38 (63.3%)

2.75 ± 0.82
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Figure
3. Results
of trimmed
pathanalysis
analysis models
models with
beta
weights,
standard
errors,
Figure
3. Results
of trimmed
path
withstandardized
standardized
beta
weights,
standard
errors,
and significance values depicting relationships of vasomotor symptoms, weight gain, difficulty
and significance values depicting relationships of vasomotor symptoms, weight gain, difficulty sleeping,
and fatigue with symptoms of anxiety (Panel a), depression (Panel b), psychological distress (Panel c),
and memory problems (Panel d) among menopausal women. * p < 0.05, ** p < 0.01. Dotted lines
represent trimmed paths.

Int. J. Environ. Res. Public Health 2020, 17, 5028

13 of 19

No associations were found between ATMS and sociodemographic and clinical characteristics
of the participants (Supplementary Materials). ATMS expressed significant negative correlations
with most menopausal symptoms—correlations with difficulty sleeping and sexual symptoms were
not significant (Table 2). Accordingly, a multiple regression model was run to check if symptoms
strongly correlated (p < 0.001) with ATMS (anxiety and psychological distress, vasomotor symptoms,
weight gain, and total MENQOL scores) may predict attitudes toward menopause. Among different
menopausal symptoms, only vasomotor symptoms and weight gain could explain 16.1% of the variance
in attitudes toward menopause. However, only vasomotor symptoms expressed a significant effect
(β = −323, p = 0.011, CI: −0.026 to −0.003, Supplementary Materials).
4. Discussion
This study investigated the hypotheses that high levels of vasomotor symptoms and increased
body weight would be associated with high sense of fatigue, sleep loss, anxiety, and depressive
symptoms, as well as overall psychological distress and memory problems. The findings support
these hypotheses. In other words, the multiplicity and severity of menopausal symptoms may
significantly endanger emotional and cognitive wellbeing in midlife women. The study also examined
the relationship between the severity of menopausal symptoms and attitudes toward menopause.
As expected, overall scores of the MENQOL scale as well as scores of its subdomains were negatively
correlated with ATMS scores, indicating higher negative attitudes toward menopause among women
with more severe symptoms. However, vasomotor symptoms seem to be the most influential in
shaping attitudes toward menopause.
In this sample, vasomotor symptoms had significant effects on symptoms of anxiety and overall
psychological distress both directly and indirectly through fatigue. On the other hand, vasomotor
symptoms had no direct effect on symptoms of depression, despite the strong correlation noticed
between these symptoms. Such absence of association may be due to the fact that this study used
rather rough measures to evaluate depressive symptoms. Incorporation of more objective outcome
indicators will certainly improve the quality of similar future studies. Nonetheless, fatigue significantly
mediated the relation between vasomotor symptoms and most psychological climacteric symptoms,
including depressive symptoms and memory problems (Figure 3). In other words, women with
more severe vasomotor symptoms would experience more severe symptoms of fatigue, anxiety,
depression, psychological distress, and cognitive alterations; the opposite is true. These finding are
consistent with those reported in other studies. In this regard, Elavsky and Gold (2009) reported a
positive direct effect of hot flashes on depressed mood and fatigue among menopausal women [27].
In accordance with our results, higher scores on the Menopause Rating Scale significantly predicted
higher scores on the Hamilton Depression Rating Scale among menopausal women in Ecuador [47].
Cumulative knowledge supports the link between menopausal symptoms (particularly, vasomotor
symptoms) and the occurrence of anxiety and depressive disorders. In this respect, a former systematic
review identified a relation between anxiety symptoms and vasomotor symptoms in nine studies;
two of them reported the prevalence of panic disorder [48]. Another review reported that vasomotor
symptoms, vaginal dryness, and dyspareunia significantly correlate with anxiety and depressive
symptoms. Poor sleep quality associated with hot flashes and night sweat also contributes to anxiety
and depressive symptoms [16]. Nevertheless, difficulty sleeping, which strongly correlated with
vasomotor symptoms in our study, had no effect on all psychological and memory outcomes. Again,
this might be related to the fact that using one item on the MENQOL scale is not sufficient to reflect on
all aspects of sleep quality.
Studies examining the role of fatigue in the relationship between vasomotor symptoms and
mood dysregulation in menopausal women are quite scarce. In line with our findings, a single
study reported a direct effect of hot flashes on depressed mood and fatigue, along with a moderate
association between depressed mood and fatigue. Both symptoms heightened perceived stress among
American peri- and postmenopausal women [27]. Studies investigating conditions with alterations
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in feminine hormones demonstrate vivid relationships between fatigue and depression. In one
study, breast cancer patients with high cognitive fatigue exhibited higher depressive and menopausal
symptoms compared with counterparts with low cognitive fatigue [49]. A recent meta-analysis reports
a strong relationship between fatigue and depressive symptoms during the first few months following
childbirth, which correspond to hormonal drop during the postpartum period [50]. Around 70%
of patients with chronic fatigue also suffer from depressive disorders and other affective problems.
Research views fatigue and mood dysregulations as co-associated disorders that represent clinical
manifestations of shared neurological pathologies related to inflammation, oxidative/nitrosative stress,
and abnormal activity of the hypothalamic–pituitary–adrenal axis [26]. On the other side, addressing
vasomotor symptoms through hypnosis is reported to reduce current fatigue and improve sleep and
quality of life in postmenopausal women [29]. Likewise, treating menopausal fatigue with armodafinil
was associated with improvement in depressive symptoms, insomnia, cognitive function, and total
scores of the MENQOL scale [23]. In the meantime, a current meta-analysis revealed that use of
armodafinil as an adjunctive treatment for depressive and bipolar disorders improves responsiveness
to antidepressants [51]. Altogether, fatigue experienced by peri- and postmenopausal women may
alter psychological wellbeing, and proper management of fatigue may be essential to prevent the
development of chronic fatigue syndrome and mood disorders.
Weight gain was a strong positive predictor of both depressive and anxiety symptoms as well as
total psychological distress among our participants. Additionaly, weight gain exerted significant
indirect effects on symptoms of anxiety, distress, and memory problems through the mediating effects of
fatigue. Consistent with our results, Elavsky and Gold (2009) reported a significant contribution of BMI
to symptoms of fatigue, depressed mood, and perceived stress among postmenopausal women [27].
Altogether, these findings emphasize the biological connections reported in the literature between sex
hormones, obesity, mood dysregulations, and cognitive performance in humans. Research denotes
that the effect of estradiol (E2) is more important than that of testosterone on the signaling pathways
involved in the development of insulin resistance in healthy, young postmenopausal women [52].
Insulin resistance is associated with mitochondrial dysfunction, high production of free radicals,
and high production of inflammatory mediators. High fat mass, a main source of adipose tissue
dysfunctions, promotes insulin resistance and systemic inflammation via activation of macrophages
and toll-like receptor 4 [53,54]. Neuroinflammation is a key pathological feature in disorders involving
mood dysregulation such as depression and anxiety [55], as well as in cognitive alterations, which occur
within the spectrum of normal cognitive aging, and in neurodegenerative disorders such as Alzheimer’s
disease [11,13–15]. In fact, obesity and metabolic syndrome—characterized mainly by dysregulated
metabolism of lipids and glucose—are independently associated with depression, and together they
synergize its inflammatory pathway and worsen depressive symptoms and cognitive functions [56,57].
Moreover, depression induced by a high-fat diet is associated with alterations in intestinal microbiota,
intestinal neuropeptides, and brain metabolome; it is also resistant to imipramine treatment [35].
On the other side, neurotrophic factors involved in high neuroinflammatory states such as ciliary
neurotrophic factor affect food intake and body weight in experimental models of obesity induced
by high-fat diet through a mechanism that involves influencing the activity of neuronal circuits and
pathways located in the arcuate nucleus of the hypothalamus [58]. The hypothalamus plays a major
role in the production of gonadotropin-releasing hormone and sex steroids [59]. Our findings, along
with this detailed biological overview, highlight the importance of monitoring changes in body weight
among menopausal women and addressing obesity as a major risk factor for neuropsychiatric disorders
such as depression, anxiety, and Alzheimer’s disease.
Data of this study displayed no associations between psychological symptoms and subject
characteristics such as age, menopausal status, etc. Consistent with our results, Olofsson and
colleagues [36] reported no association between menopausal status and menopausal symptoms (except
for vasomotor symptoms and joint pain) among menopausal women in Sweden. Likewise, the intensity
of menopausal symptoms among Iranian women correlated only with marital status and husbands’
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level of education [60]. On the contrary, these findings are incongruent with those reported among
Jordanian and Lebanese women [9,10] where the severity and occurrence of overall menopausal
symptoms correlated with age, family income, level of education, parity, perceived health status,
and menopausal status. This discrepancy may be related to the fact that most participants in the current
study were postmenopausal, which implies minor differences in variables related to age and health
status. In addition, the socioeconomic level in the UAE (an oil-rich and economically vivid country) is
different from occupied countries like Lebanon and Jordan. In this respect, further investigations that
compare differences between menopausal women in different Arab countries are necessary.
Overall, attitude mean score in this sample represents mild to moderate positive attitudes toward
menopause. Sociodemographic and clinical characteristics were not correlated with attitudes toward
menopause. On the other hand, increases in the degree of being upset about encountering anxiety
symptoms, vasomotor symptoms, distress symptoms, sexual symptoms, overall MENQOL symptoms,
and weight gain (the latter may reflect dissatisfaction with body image) were associated with a
reduction in attitude scores, i.e., a rise in negative attitudes. A number of studies report consistent
findings. In this regard, aged Turkish women who experienced fewer depressive symptoms and
more positive body image experienced more positive attitudes towards menopause compared with
women with more depressive symptoms and body image disturbance [19]. Similarly, attitudes toward
menopause in climacteric Iranian women were significantly affected by excessive night sweat, poor
memory, and sleeplessness [60]. An existing systematic review reports that in ten out of thirteen studies,
negative attitudes are associated with symptoms severity during menopause transition [61]. In our
study, attitudes could not significantly predict any of the neuropsychiatric symptoms (Supplementary
Materials). Altogether, these findings denote that experiencing intense menopausal symptom may
promote the development of negative attitudes toward menopause.
5. Strengths and Limitations
Apart from confirming the main role of vasomotor symptoms in psychological distress, this study
also shows that fatigue and changes in body composition that follow estrogen drop during menopause,
particularly weight gain, are key contributors to psychological distress among menopausal women.
Crucial practical implications can be derived from these findings. In this context, various levels of
responses may be adopted to improve quality of life in midlife women by addressing vasomotor
symptoms, fatigue, and distress. At the level of healthcare systems and work organizations, prompt
identification of women in need for specific psychological care is essential. It is critical that appropriate
care should be delivered in a sensitive and non-stigmatizing manner. Organizational support should be
properly tailored to promote the development of social support networks and provide interventions that
address matters of fatigue, stress, exhaustion, and burnout among working menopausal women [4,22].
Such interventions may include mindfulness classes and well-designed physical activity. The latter is
a common effective treatment of depressive/anxiety disorders and fatigue [26], and it is reported to
abolish vasomotor symptoms in menopausal women. However, the responsiveness of women with
high fat mass is rather limited [27]. Hence, weight control measures such as diurnal intermittent fasting
and dietary interventions (e.g., caloric restriction, high fiber diet, and herbal supplements) may be
beneficial [3,62]. Reports from studies employing hypnosis and armodafinil in menopausal women
uncovered multidimensional effects, including improvements in fatigue, sleep, emotional response,
and quality of life [23,29]. On the personal level, it might be important that menopausal women
receive structured education about the nature of menopause [4,10]. Cognitive behavioral interventions,
similar to those used for patients suffering from depression or anxiety, may be helpful—for example,
helping patients learn and practice monitoring changes in their mood, sleep, cognition, and vasomotor
symptoms in response to stressful events, social interactions, food intake and the like. This strategy,
from a theoretical point of view, may help these women restructure their personal resources to promote
better coping and develop higher levels of resilience. However, research is needed to evaluate the
effectiveness of self-monitoring and self-care strategies among midlife women.
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Despite the insights provided by the current study, it has a number of limitations, which may limit
generalizability of the findings. First, the sample size is relatively small, although a power analysis was
estimated before data collection [4]. Based on a previous study reporting a strong correlation between
scores of the MENQOL scale and BDI [42], variables reflecting on symptoms of fatigue, sleep loss,
memory problems, depression, and anxiety were derived from the MENQOL scale instead of being
estimated by specific measures (e.g., Mini-Mental State Examination or BDI), which may have resulted
in measurement errors. Furthermore, it was not possible to test the validity (e.g., dimensionality
and factorial purity) of the MENQOL and ATMS because of the small sample size, albeit results of
reliability testing indicate good internal consistency of both scales. In addition, weight gain was
subjectively reported by the participants and not objectively measured, which may infer some degree
of self-reported bias (e.g., body image disturbance) rather than actual fatness. Lack of assessment
of psychological symptoms before the onset of menopause as well as using a cross-sectional design
cast doubt on the direction of the hypothesized relationships in the current study. In this sense,
there is a possibility that women with higher levels of mood dysregulation develop chronic fatigue,
which increases bodily distress by increasing the release of cytokines and free radical, resulting in more
severe vasomotor symptoms. Therefore, it is necessary that future studies test the plausibility of the
causal pathways involving vasomotor symptoms, fatigue, and emotional distress. This study did not
address other important alternative causal pathways such as social support, physical activity, coping
style, and levels of resilience—which may also need further exploration in future investigations.
6. Conclusions
Vasomotor symptoms and weight gain contribute to fatigue, mood dysregulation, sleep
disturbance, memory problems, and overall distress among menopausal women. The relationship
between these variables is either direct or mediated by fatigue. Most menopausal symptoms correlate
with negative attitudes toward menopause; however, only vasomotor symptoms could predict
negative attitudes toward menopause. Overall, these findings signify a widespread of psychological
distress among menopausal women and highlight a key role of vasomotor symptoms, fatigue,
and obesity in the development of psychological distress and negative attitudes toward menopause
(only vasomotor symptoms). Hence, special measures directed toward mitigation of fatigue and
alleviation of psychological distress may be beneficial.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-4601/17/14/5028/s1,
Factor analysis of the MENQOL scale, Correlations between psychological variables and ATMS with
sociodemographic and clinical characteristics, Regression model predicting ATMS, and Overall summary of the
output of path analysis.
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